NewAmsterdam Pharma Company N.V. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NAMS Nasdaq 2830 www.newamsterdampharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NewAmsterdam Pharma Company N.V.

A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness - Jun 11th, 2026 4:11 am
Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026 - Jun 8th, 2026 8:29 am
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions - Jun 3rd, 2026 6:00 am
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge - May 30th, 2026 12:12 pm
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - May 30th, 2026 10:48 am
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - May 28th, 2026 6:00 am
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - May 11th, 2026 10:37 am
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May - May 11th, 2026 6:41 am
Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses? - May 8th, 2026 1:19 am
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends - May 8th, 2026 12:06 am
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 6:50 am
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - May 7th, 2026 5:00 am
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 2:57 pm
A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results - Apr 9th, 2026 10:16 am
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Apr 8th, 2026 2:29 pm
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 6:00 am
Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4 - Apr 2nd, 2026 7:41 am
Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) - Mar 29th, 2026 5:05 pm
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session - Mar 23rd, 2026 6:00 am
This Biotech Was Quietly Bought Before a $58 Per Share Takeout - Mar 21st, 2026 5:15 pm